Evidence map›Paper›PMID 40035876›Full record

ArticleCancer immunology, immunotherapy : CII2025

Development of a T cell engaging bispecific antibody targeting long non-coding RNA PVT1.

Hirotaka Kato, Tomohide Tsukahara, Kenji Murata, Hiromu Nishikata, Yuka Mizue, Takashi Sasaya, Terufumi Kubo, Takayuki Kanaseki, Yoshihiko Hirohashi, Atsushi Oyagi and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hirotaka KatoDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Tomohide TsukaharaDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan. tukahara@sapmed.ac.jp.
Kenji MurataDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Hiromu NishikataDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Yuka MizueDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Takashi SasayaDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Terufumi KuboDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Takayuki KanasekiDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Yoshihiko HirohashiDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Atsushi OyagiOncology Clinical Exploratory Research II, Ono Pharmaceutical, Co., Ltd., 1-8-2, Kyutaro-Machi, Chuo-Ku, Osaka, Osaka, 541-8564, Japan.
Tatsuo MaedaResearch Center of Oncology Group VI, Ono Pharmaceutical, Co., Ltd., 1-8-2, Kyutaro-Machi, Chuo-Ku, Osaka, Osaka, 541-8564, Japan.
Akihiro MiyazakiDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.
Toshihiko TorigoeDepartment of Pathology, School of Medicine, Sapporo Medical University, South-1, West-17, Chuo-Ku, Sapporo, Hokkaido, 060-8556, Japan.

Funding

AMED 24ama221328h0002Japan Agency for Medical Research and Development 21cm0106309h0006Japan Society for the Promotion of Science 20H03807
6 · The paper itself

Abstract

The development of effective immunotherapies for solid tumors remains a significant challenge. In previous studies, we identified PVT1, a long non-coding RNA, with the peptide HF10 derived from PVT1, presented by HLA-A24. This study aims to develop a single-chain variable fragment (scFv) that specifically recognizes the HLA-A24/HF10 complex (HF10 scFv) and to evaluate its specificity, reactivity, and therapeutic potential as part of a T cell engaging bispecific antibody (HF10xCD3) in vitro and in vivo. Using a scFv phage display library, we screened for scFv clones targeting the HLA-A24/HF10 peptide complex. The selected HF10 scFv was engineered into an IgG1 format (HF10-hIgG1), which demonstrated high affinity (K

Indexed as

Antibodies, BispecificHLA-A24 AntigenImmunotherapyRNA, Long NoncodingT-LymphocytesAnimalsFemaleHumansK562 CellsMiceMice, Inbred NODMice, SCIDXenograft Model Antitumor AssaysAntibodies, BispecificHLA-A*24:02 antigenHLA-A24 AntigenPVT1 long-non-coding RNA, humanRNA, Long NoncodingCarcinomaCTL epitopeHLA-A24Long non-coding RNAOsteosarcomaPeptide

Identifiers

PMID40035876
PMCPMC11880442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.